SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 [Yahoo! Finance]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: Yahoo! Finance
Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 SLS009, alternatively known as tambiciclib, is a selective CDK9 inhibitor. Put simply, this is a treatment designed to stop a specific “worker” protein in human cells called CDK9. SELLAS said it will present the data in a poster session. That is, instead of giving a formal speech on the stage at the San Diego Convention Center, the company will only display a printed poster. The poster, titled “Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines,” centers on the drug's mechanism of action in acute myeloid leukemia, or AML, the company said in a press release statement. According to preclinical data, said SELLAS, SLS009 retained its activity in AML models carrying ASXL1 and TP53 mutations. To the company
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run [Yahoo! Finance]Yahoo! Finance
- SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences GAAP EPS of -$0.25 beats by $0.01 [Seeking Alpha]Seeking Alpha
SLS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form S-3ASR
- 3/19/26 - Form 8-K
- SLS's page on the SEC website